Monopar Therapeutics (NASDAQ:MNPR) rose around 20% ahead of trading on Thursday after it announced an agreement with Alexion, AstraZeneca Rare Disease, the group within AstraZeneca (NASDAQ:AZN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results